	US 11,981,720 B2
	Use novel light sensitive channel protein VR 1.0 in preparation of retinal photoreceptor cell degenerative disease drug
Yin Shen, Hubei (CN)
Assigned to ZHONGMOU THERAPEUTICS CO., LTD., Hubei (CN)
Filed by ZHONGMOU THERAPEUTICS CO., LTD., Hubei (CN)
Filed on Mar. 10, 2023, as Appl. No. 18/120,007.
Application 18/120,007 is a continuation of application No. PCT/CN2022/097893, filed on Jun. 9, 2022.
Claims priority of application No. 202110388643.8 (CN), filed on Apr. 12, 2021.
Prior Publication US 2023/0348552 A1, Nov. 2, 2023
Int. Cl. A61P 27/02 (2006.01); C07K 14/705 (2006.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01); A61K 48/00 (2006.01)

CPC C07K 14/705 (2013.01) [A61P 27/02 (2018.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 48/00 (2013.01); C12N 2750/14143 (2013.01)]

5 Claims

1. A light-sensitive channel protein VR1.0, wherein the amino acid sequence of the light-sensitive channel protein VR1.0 comprises SEQ ID NO: 1.